Valuation: BioSenic SA

Market Cap 1.5M 1.65M 1.39M 1.25M 2.36M 155M 2.45M 16.68M 6.61M 83.28M 6.2M 6.07M 264M P/E 2023
-0.29x
P/E 2024 -0.28x
Enterprise Value 28.84M 31.74M 26.64M 24.07M 45.42M 2.98B 47.02M 320M 127M 1.6B 119M 117M 5.07B EV / Sales 2023
113x
EV / Sales 2024 286x
Free-Float
92.39%
Yield 2023 *
-
Yield 2024 -
6 months-9.09%
Current year-13.04%
1 week 0
Extreme 0.002
0
1 month 0
Extreme 0.002
0
Current year 0
Extreme 0.0018
0
1 year 0
Extreme 0.0018
0
3 years 0
Extreme 0.0012
0.1
5 years 0
Extreme 0.0012
0.35
10 years 0
Extreme 0.0012
0.35
Manager TitleAgeSince
Chief Executive Officer 55 29/09/2024
Director TitleAgeSince
Director/Board Member 55 31/12/2021
Chairman - 31/08/2025
Director/Board Member - 28/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-9.09%-96.21% 1.44M
-0.82%+1.40%+40.13%+143.17% 1,286B
-1.12%+0.16%+41.57%+88.24% 688B
-0.16%+0.43%+25.88%+113.01% 521B
+1.14%+4.87%+43.06%+71.97% 386B
-2.23%-2.89%+55.57%+41.64% 364B
+1.27%+2.01%+30.01%+62.35% 302B
+0.37%+0.75%+3.71%+39.09% 287B
-0.72%-0.63%+35.30%+71.87% 252B
-0.30%-1.03%+35.05%+124.88% 208B
Average +0.10%+1.87%+30.12%+66.00% 429B
Weighted average by Cap. -0.12%+3.26%+36.53%+98.00%

Financials

2023 2024
Net sales 336K 370K 310K 280K 529K 34.73M 548K 3.73M 1.48M 18.64M 1.39M 1.36M 59.03M 102K 112K 94.24K 85.13K 161K 10.54M 166K 1.13M 449K 5.66M 421K 412K 17.92M
Net income -28.78M -31.68M -26.59M -24.02M -45.32M -2.97B -46.92M -320M -127M -1.6B -119M -116M -5.06B -4.77M -5.25M -4.41M -3.98M -7.51M -493M -7.77M -52.98M -20.99M -264M -19.69M -19.28M -838M
Net Debt 28.04M 30.87M 25.91M 23.4M 44.16M 2.9B 45.72M 312M 123M 1.56B 116M 113M 4.93B 27.34M 30.09M 25.26M 22.81M 43.05M 2.83B 44.57M 304M 120M 1.52B 113M 111M 4.8B
Projected Income Statement - Annual - BioSenic SA
Logo BioSenic SA
BioSenic SA is a biotechnology company with extensive scientific and clinical experience in the field of orthopedics and regenerative therapies, specializing in the clinical development of therapies for bone and cartilage repair. BioSenic SA still holds stakes in its clinical assets ALLOB and JTA, but is now focusing on joint development with 4Moving Biotech of a GLP-1-based disease-modifying therapy for veterinary use, particularly for recovery after ligament surgery in dogs. BioSenic SA is also focusing on other potential new partnerships.
Employees
-
Date Price Change Volume
16/11/26 €0.002000 0.00% 0
13/11/26 €0.002000 0.00% 0
12/11/26 €0.002000 0.00% 0
11/11/26 €0.002000 0.00% 0
10/11/26 €0.002000 0.00% 0

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - BioSenic SA
  1. Stock Market
  2. Stocks
  3. BIOS Stock